- KDNY Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Chinook Therapeutics (KDNY) 8-K20 Jun 23CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysFinancial data
Company Profile